Abstract

The etiopathogenesis of late-onset Alzheimer’s disease (AD) is increasingly recognized as the result of the combination of the aging process, toxic proteins, brain dysmetabolism, and genetic risks. Although the role of mitochondrial dysfunction in the pathogenesis of AD has been well-appreciated, the interaction between mitochondrial function and genetic variability in promoting dementia is still poorly understood. In this study, by tissue-specific transcriptome-wide association study (TWAS) and further meta-analysis, we examined the genetic association between mitochondrial solute carrier family (SLC25) genes and AD in three independent cohorts and identified three AD-susceptibility genes, including SLC25A10, SLC25A17, and SLC25A22. Integrative analysis using neuroimaging data and hippocampal TWAS-predicted gene expression of the three susceptibility genes showed an inverse correlation of SLC25A22 with hippocampal atrophy rate in AD patients, which outweighed the impacts of sex, age, and apolipoprotein E4 (ApoE4). Furthermore, SLC25A22 downregulation demonstrated an association with AD onset, as compared with the other two transcriptome-wide significant genes. Pathway and network analysis related hippocampal SLC25A22 downregulation to defects in neuronal function and development, echoing the enrichment of SLC25A22 expression in human glutamatergic neurons. The most parsimonious interpretation of the results is that we have identified AD-susceptibility genes in the SLC25 family through the prediction of hippocampal gene expression. Moreover, our findings mechanistically yield insight into the mitochondrial cascade hypothesis of AD and pave the way for the future development of diagnostic tools for the early prevention of AD from a perspective of precision medicine by targeting the mitochondria-related genes.

Details

Title
Hippocampal transcriptome-wide association study and pathway analysis of mitochondrial solute carriers in Alzheimer’s disease
Author
Tian, Jing 1 ; Jia, Kun 1 ; Wang, Tienju 1 ; Guo, Lan 1 ; Xuan, Zhenyu 2 ; Michaelis, Elias K. 3 ; Swerdlow, Russell H. 4   VIAFID ORCID Logo  ; Du, Heng 5   VIAFID ORCID Logo 

 University of Kansas, Department of Pharmacology and Toxicology, Lawrence, USA (GRID:grid.266515.3) (ISNI:0000 0001 2106 0692) 
 The University of Texas at Dallas, Department of Biological Sciences, Richardson, USA (GRID:grid.267323.1) (ISNI:0000 0001 2151 7939) 
 University of Kansas, Department of Pharmaceutical Chemistry, Lawrence, USA (GRID:grid.266515.3) (ISNI:0000 0001 2106 0692) 
 University of Kansas Medical Center, Alzheimer’s Disease Research Center, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375) 
 University of Kansas, Department of Pharmacology and Toxicology, Lawrence, USA (GRID:grid.266515.3) (ISNI:0000 0001 2106 0692); University of Kansas Medical Center, Alzheimer’s Disease Research Center, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375) 
Pages
250
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3066163342
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.